[1]

QI Linling, LIU Shourong. Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.

[2]

MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.

[3]

TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao. Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.

[4]

LI Qian, LV Hong, LIU Yue, SHI Jia. Efficacy and safety of antifibrinolytic therapy in the perioperative cardiovascular surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 830-835.

[5]

WANG Nana, TAN Xiaofeng, MA Tao, CHENG Yusheng. Current situation and future perspectives of treatment of chronic pulmonary aspergillosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 217-222.

[6]

LI Hongpeng, ZHANG Liu, LI Qingyun. Mechanism and advance of COVID-19 on immune related pathogenesis and immunotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1288-1294.

[7]

WANG Weilu, MAO Yicheng, ZHU Yizhun. Research progress of autophagy in viral pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1315-1320.

[8]

MU Xin, ZHAO Ying, ZHANG Lan, CUI Yimin, ZHANG Yongxiang, DU Guanhua. Drug clinical trial of COVID-19 in China: A brief analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 869-877.

[9]

ZHANG Zhengfu, LI Meng, WANG Jianan. Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 421-425.

[10]

LIU Qi, XIA Shuai, JIANG Shibo. Research and development of antiviral drugs against new coronavirus 2019-nCoV [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 241-245.

[11]

CUI Cheng, YAO Xueting, TU Siqi, XIE Jieen, LI Haiyan, LIU Dongyang. Advances of the clinical pharmacology of hydroxychloroquine sulfate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 221-226.

[12]

LUO Yi, JIANG Zhiwei. Statistical consideration in the design of COVID-19 clinical trials in emergency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 121-125.

[13]

LAN Qiaoshuai, XIA Shuai, ZHOU Jie, WANG Qian, LU Lu. New use of old drugs in the treatment of SARS-CoV-2 infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 126-134.

[14]

HU Ke. New coronavirus pneumonia: Question and confusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 141-143.

[15]

HUANG Xinyi, GUO Fei, ZENG Xiangchang, OUYANG Dongsheng. Short-chain fatty acids as signal molecules in intestinal inflammation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1293-1299.

PDF (PC)

Knowledge